Januvia patent?

When does the Januvia patent expire?

Januvia, a medication developed by Merck & Co. to help manage type 2 diabetes, is covered by a patent [1] held by the pharmaceutical company. The patent for Januvia (sitagliptin) is set to expire in 2025, as reported by DrugPatentWatch.com [2]. This expiration date marks the end of Merck's exclusivity period for the medication in the United States.

How long will Januvia remain patent-protected internationally?

While the patent for Januvia is set to expire in the United States in 2025, its exclusivity period varies by country. Merck has secured patent protection for the medication in many countries, including Europe, Canada, and Japan, but the exact expiration dates differ. According to DrugPatentWatch.com, the patent for Januvia in the European Union is expected to expire in 2025, while in Japan, it is expected to expire in 2026 [3].

Will biosimilars enter the market before the patent expires?

Under U.S. law, biosimilars can potentially be approved before the patent expires, as long as the applicant demonstrates that the biosimilar is bioequivalent and does not infringe on the innovator's patent [4]. While Merck could challenge any biosimilar applications filed before the patent expires, biosimilars could still potentially enter the market before the patent expiration date.

References:

[1] U.S. Patent 6,613,742 B1 (assigned to Merck Sharp & Dohme Corp.)
[2] DrugPatentWatch.com. (n.d.). Sitagliptin (Januvia) patent data. Retrieved from https://drugpatentwatch.com/patent/6,613,742
[3] DrugPatentWatch.com. (n.d.). Sitagliptin (Januvia) patent data. Retrieved from https://drugpatentwatch.com/patent/EPA/EP1845113-A1
[4] 21 U.S.C. § 355(j)(5)(C).